Johnson & Johnson (JNJ) fair value analysis
S&P 500 · Updated 2026-10-19
JNJ price how computed
Forward Fair Value verdict
OvervaluedJNJ is trading at more than a 25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $261.44
- Sector
- Healthcare
- 12-month range
- $186.00–$278.43
- Market cap
- $630B
- From 52-week high
- -6.1%
- Shares outstanding
- 2.41B
- Rank in Healthcare by discount to fair value
- #87 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Johnson & Johnson is a diversified healthcare company that develops, manufactures, and markets pharmaceuticals, medical devices, and consumer health products across multiple therapeutic areas and disease categories. The company operates globally with a presence in numerous countries across North America, Europe, Asia-Pacific, Latin America, and other regions worldwide.
JNJ currently ranks #87 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $630B
- P/E (trailing)
- 25x
- Revenue (TTM)
- $99.3B
- Net margin
- 16.2%
- EPS (TTM)
- $10.65
- Gross margin
- 73.0%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 6.2%
- Shares outstanding
- 2.41B
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 40 · neutral
- 50-day average
- $265.23
- 200-day average
- $244.12
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $5.28 per share (4 payments)
- Yield on last price
- 2.02%
- Consecutive years of increases
- 23
- Next ex-dividend date
- 2026-11-24
- Last payment date
- 2026-09-08
Earnings how computed
- Last 8 quarters vs consensus
- 7 beat, 0 missed
- Quarter by quarter
- 2026-09 ▲ beat (+2.4%)
2026-06 ▲ beat (+2.1%)
2026-03 ▲ beat (+0.7%)
2025-12 ▬ met (0.0%)
2025-09 ▲ beat (+1.4%)
2025-06 ▲ beat (+3.4%)
2025-03 ▲ beat (+7.4%)
2024-12 ▲ beat (+1.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 16 buy · 6 hold · 1 sell (23 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $279
- Target vs last price
- +6.7%
What our data shows for JNJ
- Our model validated 17 trailing price-to-earnings windows for JNJ, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $186.00–$278.43.
- The 14-day relative strength index sits at a neutral 40.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for JNJ
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent JNJ news
TickrTrends' derived news-sentiment signal for JNJ is currently leaning positive, computed from recent coverage.
- Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors (manilatimes.net, 2026-10-20)
TickrTrends take: Mestag Therapeutics, a company in which Johnson & Johnson has invested, announced board appointments that could influence the development trajectory of its pipeline candidates. Given TickrTrends' current assessment that JNJ is overvalued, investors should monitor whether Mestag's strategic leadership changes generate sufficient clinical or commercial progress to justify JNJ's current valuation in the Healthcare sector. Any meaningful advancement in Mestag's programs would need to demonstrate substantial value creation to address the overvaluation concern at the parent investment level. - Johnson & Johnson’s Dividend Machine Is Running. Can Earnings Keep Up? (insidermonkey.com, 2026-10-20)
TickrTrends take: Johnson & Johnson's track record of consistent dividend payments has positioned it as an income-focused holding, but the overvalued verdict from TickrTrends suggests the current market price may not fully align with underlying earnings generation. For valuation-conscious investors, the critical question is whether JNJ's earnings growth trajectory can justify its current valuation premium, particularly given the competitive pressures and patent expirations common to the Healthcare sector. Monitoring the gap between dividend sustainability and actual earnings growth will be essential for assessing whether the stock's valuation multiple can be supported over time. - JNJ DCF Analysis: Intrinsic Value $101 vs Price $256 (gurufocus.com, 2026-10-19)
TickrTrends take: Johnson & Johnson trades at a significant premium to its discounted cash flow derived intrinsic value, which aligns with TickrTrends' current overvalued assessment of the stock. The substantial gap between the DCF valuation and market price suggests that current market pricing reflects expectations beyond what traditional cash flow analysis supports. Investors focused on valuation metrics may want to monitor whether upcoming earnings reports or guidance changes narrow this valuation differential.
More JNJ news
- Here's our monthly update on our 32 stocks, including 2 more names to buy (cnbc.com, 2026-10-15)
- After 20 Years, AdVenture Games Is Reintroducing Team Building as an Experience Worth Remembering (prweb.com, 2026-10-15)
- EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe (manilatimes.net, 2026-10-15)
- [DowJonesToday]Dow Jones Slips as Inflation Concerns Dampen Market Sentiment (thestockmarketwatch.com, 2026-10-14)
- JNJ Maintains by Wells Fargo -- Price Target Lowered to $275 (gurufocus.com, 2026-10-14)
- Oil Prices Surge Amid Geopolitical Tensions and Supply Risks as Markets Close Mixed (thestockmarketwatch.com, 2026-10-12)
- Is JNJ Overvalued? DCF Says Worth $127 (gurufocus.com, 2026-10-12)
- [DowJonesToday]Dow Jones Gains Slightly as Investors Eye CPI and Earnings (thestockmarketwatch.com, 2026-10-12)
What people are saying
Follow the JNJ conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for JNJ showed mixed movements this week. The DCF cross-check band shifted from overvalued to none, while the balance-sheet leverage band improved from moderate to low. However, the quality grade declined from B to D, reflecting a deterioration in the company's quality metrics despite the more favorable leverage position.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for JNJ show that the quality grade improved from C to B this week. The stock maintains an overvalued valuation verdict. JNJ operates in the Healthcare sector.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is JNJ stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), JNJ is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is JNJ's TickrTrends verdict?
JNJ's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does JNJ compare to other Healthcare stocks?
JNJ ranks #87 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is JNJ overbought or oversold?
JNJ's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does JNJ pay a dividend?
Yes. JNJ paid $5.28 per share over the last twelve months (4 payments), a 2.02% yield on TickrTrends' last price, and has raised the annual total for 23 consecutive years. The next ex-dividend date on file is 2026-11-24.
Does JNJ usually beat earnings estimates?
Over its last 8 reported quarters JNJ beat the consensus estimate 7 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about JNJ?
Of 23 analysts covering JNJ, 16 rate it a buy, 6 a hold and 1 a sell - buy-leaning, with a consensus price target of $279 (+6.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
JNJ vs ALKS · JNJ vs AQST · JNJ vs AZTA · JNJ vs CDNA · JNJ vs CLOV